Advisors Asset Management Inc. Cuts Stock Holdings in Medtronic PLC $MDT

Advisors Asset Management Inc. reduced its stake in shares of Medtronic PLC (NYSE:MDT) by 11.8% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 141,791 shares of the medical technology company’s stock after selling 18,940 shares during the quarter. Advisors Asset Management Inc.’s holdings in Medtronic were worth $13,504,000 at the end of the most recent quarter.

Other large investors have also recently modified their holdings of the company. Signet Investment Advisory Group Inc. lifted its position in Medtronic by 7.6% in the third quarter. Signet Investment Advisory Group Inc. now owns 26,692 shares of the medical technology company’s stock valued at $2,542,000 after purchasing an additional 1,895 shares during the last quarter. Center for Financial Planning Inc. increased its stake in shares of Medtronic by 7.2% in the third quarter. Center for Financial Planning Inc. now owns 5,212 shares of the medical technology company’s stock worth $496,000 after buying an additional 348 shares during the period. Stratos Wealth Partners LTD. increased its stake in shares of Medtronic by 24.2% in the third quarter. Stratos Wealth Partners LTD. now owns 81,813 shares of the medical technology company’s stock worth $7,792,000 after buying an additional 15,957 shares during the period. Stratos Investment Management LLC raised its holdings in Medtronic by 3.8% during the 3rd quarter. Stratos Investment Management LLC now owns 34,258 shares of the medical technology company’s stock valued at $3,263,000 after buying an additional 1,261 shares during the last quarter. Finally, Baader Bank Aktiengesellschaft boosted its position in Medtronic by 2.6% during the 3rd quarter. Baader Bank Aktiengesellschaft now owns 11,990 shares of the medical technology company’s stock valued at $1,142,000 after buying an additional 303 shares during the period. Hedge funds and other institutional investors own 82.06% of the company’s stock.

Medtronic Stock Down 0.3%

Shares of Medtronic stock opened at $101.37 on Wednesday. Medtronic PLC has a 1 year low of $79.55 and a 1 year high of $106.33. The firm has a market cap of $129.96 billion, a price-to-earnings ratio of 27.32, a PEG ratio of 2.68 and a beta of 0.71. The company has a 50-day moving average of $99.36 and a 200 day moving average of $96.28. The company has a debt-to-equity ratio of 0.57, a current ratio of 2.42 and a quick ratio of 1.80.

Medtronic (NYSE:MDT) last announced its quarterly earnings data on Tuesday, November 18th. The medical technology company reported $1.36 earnings per share for the quarter, topping analysts’ consensus estimates of $1.31 by $0.05. Medtronic had a net margin of 13.71% and a return on equity of 14.86%. The business had revenue of $8.96 billion for the quarter, compared to analysts’ expectations of $8.86 billion. During the same quarter in the prior year, the company earned $1.26 earnings per share. The business’s revenue was up 6.6% compared to the same quarter last year. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. As a group, sell-side analysts anticipate that Medtronic PLC will post 5.46 earnings per share for the current fiscal year.

Medtronic Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, January 16th. Shareholders of record on Friday, December 26th were paid a dividend of $0.71 per share. The ex-dividend date was Friday, December 26th. This represents a $2.84 dividend on an annualized basis and a yield of 2.8%. Medtronic’s payout ratio is presently 76.55%.

Medtronic News Roundup

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Medtronic agreed to acquire CathWorks for $585 million — expands its cath-lab/FFR imaging capabilities and strengthens the cardiovascular franchise, a strategic tuck-in that could accelerate revenue and cross‑sell opportunities. Medtronic to Buy CathWorks for $585M
• Positive Sentiment: Needham upgraded MDT to a “buy” and set a $121 price target (~19% upside from current levels) — the upgrade can attract buying interest and supports near-term sentiment. Needham upgrades Medtronic (MDT)
• Positive Sentiment: Analysts and trade press note new product momentum and related rating boosts — fresh product launches/approvals bolster growth narrative and margin leverage over time. Medtronic stock gets a ratings boost on new products
• Positive Sentiment: Outlook drivers: Zacks highlights strength in Medtronic’s cardiovascular unit as a likely lift to Q3 revenue (projected ~7.3% y/y), which could offset softer EPS. Strength in Cardiovascular Unit Likely to Lift MDT’s Q3 Performance
• Neutral Sentiment: MDT is expected to report earnings this week — the print and any revised FY guidance remain the primary short-term catalyst. Medtronic (MDT) Expected to Announce Earnings on Tuesday
• Neutral Sentiment: Analyst/market narratives are shifting as Medtronic’s strategic moves and pipeline progress get priced in — read for context on repositioning and valuation. How Recent Moves Are Quietly Rewriting The Story For Medtronic (MDT)
• Neutral Sentiment: Market note: the stock recently dipped while broader markets gained — a short-term trading signal but not a fundamental verdict. Medtronic (MDT) Stock Dips While Market Gains: Key Facts
• Negative Sentiment: An antitrust verdict awarded roughly $381.7M in damages against Medtronic — this legal cost and any follow‑on litigation/settlement risk can pressure near‑term earnings and valuation multiples. A Look At Medtronic (MDT) Valuation After Major Antitrust Verdict And US$381.7m Damages Award

Analyst Ratings Changes

A number of equities analysts have issued reports on the stock. Leerink Partners set a $120.00 price objective on shares of Medtronic and gave the company an “outperform” rating in a research report on Wednesday, November 19th. Truist Financial cut their target price on Medtronic from $110.00 to $107.00 and set a “hold” rating on the stock in a research note on Thursday, December 18th. Wall Street Zen upgraded Medtronic from a “hold” rating to a “buy” rating in a report on Friday, January 23rd. Weiss Ratings reiterated a “buy (b-)” rating on shares of Medtronic in a report on Monday, December 29th. Finally, William Blair upgraded Medtronic from a “market perform” rating to an “outperform” rating in a research report on Tuesday, January 6th. Sixteen research analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the stock. Based on data from MarketBeat.com, Medtronic currently has a consensus rating of “Moderate Buy” and a consensus target price of $111.21.

Medtronic Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).